CS MEDICA announces that CANNORDIC India Pvt. Ltd. is Established to Expand Presence in India
CS MEDICA A/S (“CS MEDICA” or the “Company”), a MedTech company specializing in Cannabis and pain management, is thrilled to announce the establishment of CANNORDIC India Pvt. Ltd is final. The Indian subsidiary is located at B-007, Param Tower CHS Ltd, Raghunath Nagar, Survewadi, Thane West-400604.
On April 14, 2023, the Company announced that its board of directors approved setting up the subsidiary in India. CANNORDIC India Pvt. Ltd. marks a significant milestone in its expansion strategy, solidifying its commitment to the Indian market and the rest of APAC.
With the vision to improve people's quality of life by merging innovation, science, and nature within healthcare, CANNORDIC India Pvt. Ltd. aims to introduce its cutting-edge medical devices with CBD, complying with all regulatory requirements and ensuring the availability of its esteemed CBD product portfolio in India.
The Local Managing Director, Kamlesh Vora, expressed his enthusiasm, stating, "We are very pleased to announce the establishment of our Indian company. This move allows us to bring our innovative CBD products to the Indian market and cater to the evolving needs of consumers."
Overseas Managing Director, and CEO of CS MEDICA A/S, Lone Henriksen, affirms, "We see great growth potential in India, especially considering the country's strength within the pharmaceutical industry. This expansion will enable us to serve our customers better, being individuals with symptoms and local strategic business partners, and aim for sustainable growth in the Indian pharmaceutical sector."
Cannordic India Pvt. Ltd. is dedicated to complying with all regulatory requirements and ensuring the availability of its esteemed CBD product portfolio in India. Through strategic partnerships and collaboration with local stakeholders, the company aims to foster sustainable growth in the Indian pharmaceutical sector.
The establishment of CANNORDIC India Pvt. Ltd. activates the start of registration of the product portfolio, with an estimated lead time from 3,5 months.